| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8446938 | European Journal of Cancer | 2011 | 8 Pages |
Abstract
These results show that BMI is an independent prognostic factor for survival in patients receiving chemotherapy, but not in patients receiving chemotherapy and targeted therapy. The possible decreased efficacy of bevacizumab in obese patients may explain this discrepant result. The role of BMI in patients receiving targeted therapy should be further tested.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Lieke H.J. Simkens, Miriam Koopman, Linda Mol, Gerrit Jan Veldhuis, Daan Ten Bokkel Huinink, Erik W. Muller, Veerle A. Derleyn, Steven Teerenstra, Cornelis J.A. Punt,